The Clinical Research Program here at VMC is recruiting as many patients as possible for this study. In this study, patients being randomized to 2.5mg BID of Apixaban vs. Placebo for 30 days post-hospitalization of 48 hours or greater for COVID-19. Please be aware that the clinical research team will be screening and approaching patients for the trial. The inclusion and exclusion are very broad and please note, usual inpatient DVT prophylaxis is not an exclusion.

Key Inclusion Criteria:
• Age ≥ 18 years
• COVID-19 positive test (PCR, antigen, or point of care test diagnosing a current infection) within 2 weeks of hospital admit date
• Hospitalized for COVID-19 infection for 48 or more hours

Please review additional details at clinicaltrials.gov.


Mike Previti, MD; Bill Park, MD; and Richard Kim, MD will be investigators on this trial and will work with the research team to order the study medication upon discharge. One of the research nurses will meet with the patient on day of discharge to provide instructions and deliver the study-provided meds.

Questions: Contact Dr. Previti or one of the research nurses, Shannon Huffaker or Kimberly Polzin via Voalte.